Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

676 recalls · Class II, newest first

Class II · Moderate risk

Estradiol Gel

Defective Container: Some packets may not be fully sealed, potentially allowing for loss of Ethanol from the product.

Completed Packaging defect Padagis US LLC D-0246-2025
Class II · Moderate risk

Silodosin Capsules

Subpotent Drug: Out of Specification (OOS) result for De hydro Impurity (0.654%) for 18 M Stability sample and low assay 94.9% (specification of NLT 95.0% NMT 105%)

Ongoing Wrong potency / content AvKARE NDC 42291-778-90 D-0229-2025
Class II · Moderate risk

Ciprofloxacin Ophth Solution

Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle

Ongoing Packaging defect Direct Rx NDC 61919-795-05 D-0364-2025
Class II · Moderate risk

Atomoxetine Capsules

CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.

Ongoing Nitrosamine impurity Glenmark Pharmaceuticals Inc., USA NDC 16714-761-01 D-0244-2025
Class II · Moderate risk

Atomoxetine Capsules

CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.

Ongoing Nitrosamine impurity Glenmark Pharmaceuticals Inc., USA NDC 16714-760-01 D-0243-2025
Class II · Moderate risk

Atomoxetine Capsules

CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.

Ongoing Nitrosamine impurity Glenmark Pharmaceuticals Inc., USA NDC 16714-759-01 D-0242-2025

Recalls by year